Celldex Therapeutics (CLDX) closed at $30.15 on November 11, 2026, down 1.6% from the previous close, on volume of 556,194 shares (30-day average 1,251,458).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 20, 2026 | Put with Delta Hedge | 17-Dec-27 28 P +7,500 Stock | 250 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Guggenheim Keeps Their Buy Rating on Celldex (CLDX)
TipRanks (Mon, 9-Nov 8:56 AM ET)
Goldman Sachs Remains a Hold on Celldex (CLDX)
TipRanks (Fri, 6-Nov 9:52 AM ET)
Cantor Fitzgerald Remains a Buy on Celldex (CLDX)
TipRanks (Fri, 6-Nov 9:46 AM ET)
Celldex (CLDX) Receives a Rating Update from a Top Analyst
TipRanks (Fri, 6-Nov 9:36 AM ET)
Celldex Wins on Strong Phase 3 CSU Results as Price Target Rises to $64
TipRanks (Fri, 6-Nov 9:00 AM ET)
Celldex Reports Third Quarter Financial Results and Provides Corporate Update
Globe Newswire (Thu, 5-Nov 4:01 PM ET)
Celldex to Present at Upcoming Investor Conferences
Globe Newswire (Wed, 4-Nov 4:01 PM ET)
PRNewswire (Mon, 12-Oct 9:10 AM ET)
Celldex Highlights Phase 3 Barzolvolimab Data With Complete Response Near 54% at 24 Weeks in CSU
Market Chameleon (Tue, 22-Sep 7:36 AM ET)
Celldex reports Phase 3 barzolvolimab CSU wins as complete response rates approach 54% by Week 24
Market Chameleon (Tue, 22-Sep 3:28 AM ET)
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Celldex Therapeutics trades on the NASDAQ stock market under the symbol CLDX.
As of November 11, 2026, CLDX stock price declined to $30.15 with 556,194 million shares trading.
CLDX has a beta of 1.19, meaning it tends to be more sensitive to market movements. CLDX has a correlation of 0.07 to the broad based SPY ETF.
CLDX has a market cap of $2.37 billion. This is considered a Mid Cap stock.
Last quarter Celldex Therapeutics reported $0 in Revenue and -$.96 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.05.
In the last 3 years, CLDX traded as high as $53.18 and as low as $14.40.
The top ETF exchange traded funds that CLDX belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
CLDX has outperformed the market in the last year with a price return of +33.0% while the SPY ETF gained +12.6%. However, in the short term, CLDX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -29.8% vs -1.5% return in SPY. But in the last 2 weeks, CLDX shares have fared better than the market returning 0.0% compared to SPY -1.3%.
CLDX support price is $29.73 and resistance is $31.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLDX shares will trade within this expected range on the day.
